Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery
开发 3 维人垂体促肾上腺皮质激素肿瘤培养物作为药物发现的临床前模型
基本信息
- 批准号:10448514
- 负责人:
- 金额:$ 34.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-09 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAdrenal GlandsArchitectureAutomobile DrivingBloodCatabolismCell AdhesionCell modelCellsCollagenCorticotropinDevelopmentDiseaseDrug InteractionsDrug ScreeningEvaluationExtracellular MatrixGenesGeneticGenomicsGrowthHormone secretionHumanHydrocortisoneImmune responseIndividualLibrariesLifeMapsMedicalMethodsModelingMolecularMonitorOperative Surgical ProceduresPathway interactionsPatientsPattern RecognitionPharmaceutical PreparationsPharmacotherapyPituitary GlandPituitary Gland AdenomaPituitary NeoplasmsPituitary-dependent Cushing&aposs diseasePre-Clinical ModelPrimary NeoplasmProductionProteinsRare DiseasesResectedResourcesScreening ResultSerial PassageSignal TransductionStructureSystemTestingTimeTissuesTranslational ResearchTumor TissueValidationVisualizationangiogenesisbiobankcheminformaticsdrug discoverydrug sensitivityexome sequencingexperienceexperimental studyfunctional genomicsgenomic platformhigh throughput screeninghigh-throughput drug screeningimmunocytochemistryimprovedindividual patientinhibitorminiaturizemultidisciplinaryneoplastic cellnovel therapeuticspersonalized medicinescreeningsingle-cell RNA sequencingsmall moleculetranscriptometranscriptomicstumor
项目摘要
Abstract
Cushing Disease (CD) is a life-threatening “orphan disease” caused by an adrenocorticotropic hormone
(ACTH)-secreting pituitary adenoma driving excess adrenal cortisol production. There is a large unmet medical
need for CD treatment. However, translational research has been greatly hampered due to unavailability of any
human pituitary corticotroph tumor cell models. Using single cell RNA-sequencing (scRNAseq) and microarray
transcriptome analysis of surgically resected human corticotroph tumors, we observed that loss of pituitary
corticotroph tumor ACTH secretion coincided with reduced angiogenesis, survival signals and immune
responses in parallel with increased collagen catabolism, cell adhesion and extracellular matrix organization.
Guided by these findings, we developed a unique 3-dimensional (3D) pituitary tumor culture system and for the
first time, we have been able to generate 3D human corticotroph tumor cultures that secrete ACTH >4 months.
We have assembled an experienced multidisciplinary team to complete 3 focused specific aims using this first
of its kind resource. Firstly, we will use whole exome sequencing to characterize the genomic landscape of our
corticotroph 3D culture biobank and compare genomic and genetic fidelity between the original corticotroph
tumor, normal blood and matched 3D corticotroph tumoroid cultures from the same individual patient.
ScRNAseq analysis of serial passages of individual patient-derived corticotroph tumor cultures will monitor for
transcriptome changes in a temporal fashion over the course of culture. The histopathological structure of our
3D corticotroph cultures at the single cell level will quantify tissue architecture so we can map corticotroph
tumoroid cellular composition and distribution. A second aim will employ a miniaturized automated system to
conduct a high throughput drug screen in our 3D corticotroph tumor cultures. Compounds will be subjected to
rigorous evaluation to define primary “hits” and validated by re-screening in triplicate using 20 concentrations
from 100µM to 20pM (2-fold dilution) to reliably calculate an EC50 for each compound. Finally, three
complementary approaches, computational cheminformatic profiling, scRNAseq to delineate transcriptomic
changes at the single cell level following drug treatment and functional genomics will be employed to explore
the MOA of validated hit compounds. This integrated interrogation of our drug screen results and the genetic
features of our patient-derived 3D tumor cultures as well as that of the original tumor tissue, will allow us to
disentangle an individual drug's mode(s) of action, and directly document drug sensitivity of individualized
parental corticotroph tumors. In summary, we will use our unique biobank of comprehensively molecularly
characterized pituitary corticotroph tumor tissues and paired derived 3D corticotroph tumor cultures to test
libraries of clincially relevant compounds. This pituitary 3D tumor culture system is transformative in the field
due to the lack of any human pituitary corticotroph tumor cell models and will pave the path for much needed
improved therapy for patients with this dreadfully disabling and often fatal disorder, Cushing disease.
摘要
库欣病(CD)是一种由促肾上腺皮质激素引起的危及生命的“孤儿病
促肾上腺皮质激素(ACTH)分泌垂体腺瘤驱动肾上腺皮质醇过量生产。有大量未满足的医疗需求
需要CD治疗。然而,翻译研究由于无法获得任何
人垂体促肾上腺皮质激素肿瘤细胞模型。使用单细胞RNA测序(scRNAseq)和微阵列
通过对手术切除的人促肾上腺皮质激素细胞瘤的转录组分析,我们观察到,
促肾上腺皮质激素肿瘤ACTH分泌与减少的血管生成、存活信号和免疫反应一致。
与增加的胶原蛋白catalysts,细胞粘附和细胞外基质组织平行的反应。
在这些发现的指导下,我们开发了一种独特的三维(3D)垂体瘤培养系统,
第一次,我们已经能够产生分泌ACTH >4个月的3D人促肾上腺皮质激素细胞肿瘤培养物。
我们已经组建了一个经验丰富的多学科团队,以完成3个集中的具体目标,首先使用
的同类资源。首先,我们将使用全外显子组测序来表征我们的基因组景观。
促肾上腺皮质激素细胞3D培养生物库,并比较原始促肾上腺皮质激素细胞之间的基因组和遗传保真度
肿瘤、正常血液和来自同一个体患者的匹配的3D促肾上腺皮质激素类肿瘤培养物。
单个患者来源的促肾上腺皮质激素细胞肿瘤培养物的连续传代的ScRNAseq分析将监测以下指标:
转录组在培养过程中以时间方式变化。我们的组织病理学结构
单细胞水平的3D促肾上腺皮质激素细胞培养物将量化组织结构,
肿瘤样细胞的组成和分布。第二个目标将采用小型化自动化系统,
在我们的3D促肾上腺皮质激素肿瘤培养物中进行高通量药物筛选。化合物将经受
严格评价,以确定主要“命中”,并通过使用20个浓度重复筛选三次进行验证
从100µM到20 pM(2倍稀释),以可靠地计算每种化合物的EC50。最后,三
互补方法,计算化学信息学分析,scRNAseq来描绘转录组学,
药物治疗后单细胞水平的变化和功能基因组学将被用来探索
验证命中化合物的MOA。这种对我们药物筛选结果和基因的综合询问
我们的患者来源的3D肿瘤培养物以及原始肿瘤组织的特征,将使我们能够
解开单个药物的作用模式,并直接记录个体化药物的药物敏感性。
亲代促肾上腺皮质激素细胞瘤总之,我们将利用我们独特的生物库,
特征性垂体促肾上腺皮质激素细胞肿瘤组织和配对衍生的3D促肾上腺皮质激素细胞肿瘤培养物,
临床相关化合物库。这种垂体3D肿瘤培养系统在该领域具有变革性
由于缺乏任何人垂体促肾上腺皮质激素肿瘤细胞模型,
为患有这种可怕的致残性和致命性疾病的患者改进治疗方法,库欣病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANTHONY P HEANEY其他文献
ANTHONY P HEANEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANTHONY P HEANEY', 18)}}的其他基金
Development of a patient-derived tumoroid culture system to explore novel medical treatments for refractory prolactinomas
开发患者源性肿瘤培养系统,探索难治性泌乳素瘤的新疗法
- 批准号:
10643450 - 财政年份:2023
- 资助金额:
$ 34.97万 - 项目类别:
Identification of TR4 Modulators for Treatment of Cushing Disease.
用于治疗库欣病的 TR4 调节剂的鉴定。
- 批准号:
10199436 - 财政年份:2021
- 资助金额:
$ 34.97万 - 项目类别:
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery
开发 3 维人垂体促肾上腺皮质激素肿瘤培养物作为药物发现的临床前模型
- 批准号:
10653709 - 财政年份:2021
- 资助金额:
$ 34.97万 - 项目类别:
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery
开发 3 维人垂体促肾上腺皮质激素肿瘤培养物作为药物发现的临床前模型
- 批准号:
10297675 - 财政年份:2021
- 资助金额:
$ 34.97万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
7904018 - 财政年份:2007
- 资助金额:
$ 34.97万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
8137007 - 财政年份:2007
- 资助金额:
$ 34.97万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
7667840 - 财政年份:2007
- 资助金额:
$ 34.97万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
7502595 - 财政年份:2007
- 资助金额:
$ 34.97万 - 项目类别:
Refined Fructose Promotes Pancreatic Cancer Growth
精制果糖促进胰腺癌生长
- 批准号:
7371529 - 财政年份:2007
- 资助金额:
$ 34.97万 - 项目类别:
ROSIGLITAZONE TREATMENT IN PATIENTS WITH CUSHINGS DISEASEROSIGLITAZONE TREAT
库欣病患者的罗格列酮治疗 罗格列酮治疗
- 批准号:
7718035 - 财政年份:2007
- 资助金额:
$ 34.97万 - 项目类别:
相似海外基金
Role of hypothalamic MC4R in glucose homeostasis via a novel neuroendocrine circuit involving the kidneys and adrenal glands
下丘脑 MC4R 通过涉及肾脏和肾上腺的新型神经内分泌回路在葡萄糖稳态中的作用
- 批准号:
10454300 - 财政年份:2021
- 资助金额:
$ 34.97万 - 项目类别:
Role of hypothalamic MC4R in glucose homeostasis via a novel neuroendocrine circuit involving the kidneys and adrenal glands
下丘脑 MC4R 通过涉及肾脏和肾上腺的新型神经内分泌回路在葡萄糖稳态中的作用
- 批准号:
10666539 - 财政年份:2021
- 资助金额:
$ 34.97万 - 项目类别:
Role of hypothalamic MC4R in glucose homeostasis via a novel neuroendocrine circuit involving the kidneys and adrenal glands
下丘脑 MC4R 通过涉及肾脏和肾上腺的新型神经内分泌回路在葡萄糖稳态中的作用
- 批准号:
10296199 - 财政年份:2021
- 资助金额:
$ 34.97万 - 项目类别:
Role of hypothalamic MC4R in glucose homeostasis via a novel neuroendocrine circuit involving the kidneys and adrenal glands
下丘脑 MC4R 通过涉及肾脏和肾上腺的新型神经内分泌回路在葡萄糖稳态中的作用
- 批准号:
10854123 - 财政年份:2021
- 资助金额:
$ 34.97万 - 项目类别:
Interaction of adrenal glands and liver in canine hepatocellular carcinoma
犬肝细胞癌中肾上腺和肝脏的相互作用
- 批准号:
20H03139 - 财政年份:2020
- 资助金额:
$ 34.97万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Role of dendritic cells in adrenal glands of healthy and arthritic rats
树突状细胞在健康和关节炎大鼠肾上腺中的作用
- 批准号:
235438724 - 财政年份:2013
- 资助金额:
$ 34.97万 - 项目类别:
Research Grants
Role of neural cell adhesion molecules in structural and functional remodeling of fetal adrenal glands
神经细胞粘附分子在胎儿肾上腺结构和功能重塑中的作用
- 批准号:
20591305 - 财政年份:2008
- 资助金额:
$ 34.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Search for the novel etiology in disorders of sex development (DSD) caused by abnormalities of adrenal glands and gonads.
寻找由肾上腺和性腺异常引起的性发育障碍 (DSD) 的新病因。
- 批准号:
16086202 - 财政年份:2004
- 资助金额:
$ 34.97万 - 项目类别:
Grant-in-Aid for Scientific Research on Priority Areas
Effects of endocrine disrupters on function of thyroid gland, adrenal glands and gonads
内分泌干扰物对甲状腺、肾上腺和性腺功能的影响
- 批准号:
11839003 - 财政年份:1999
- 资助金额:
$ 34.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Roles of Thyroid and Adrenal glands in the regulation of hypothalamo-hypophysial-ovarian axis in the rat.
甲状腺和肾上腺在大鼠下丘脑-垂体-卵巢轴调节中的作用。
- 批准号:
06660375 - 财政年份:1994
- 资助金额:
$ 34.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)